ONI Welcomes Dr. Alex Aravanis, MD, PhD, as Newest Board Member

FOR IMMEDIATE RELEASE

ONI Welcomes Dr. Alex Aravanis, MD, PhD, as Newest Board Member

SAN DIEGO, November 14, 2023 –

ONI is delighted to announce the appointment of Dr. Alex Aravanis, MD, PhD, as the newest member of its esteemed board of directors. Dr. Aravanis brings a wealth of expertise and experience to the team, further strengthening ONI’s commitment to innovation and excellence.

His impressive career includes notable positions such as Chief Technology Officer, SVP, Head of Research and Product Development at Illumina, and Co-Founder of GRAIL. Throughout his career, Dr. Aravanis has been at the forefront of pioneering advancements in genomics and healthcare technology.

At Illumina, Dr. Aravanis led all aspects of R&D, from early-stage research through on-market support, and was responsible for the company’s R&D for assays, arrays, sequencers, and software. During his tenure, the number of product launches and the level of innovation achieved its highest levels to date. Dr. Aravanis is known for his ability to create R&D teams that can turn technology into differentiated products and substantial commercial impact.

At GRAIL, Dr. Aravanis led the team that developed their groundbreaking multi-cancer early detection test. This effort included the most extensive clinical studies in genomic medicine, generating vast datasets to support its products. Before his tenure at GRAIL, Dr. Aravanis held the position of Senior Director of Research and Development at Illumina, Inc.

Dr. Aravanis holds a Bachelor of Science in Electrical Engineering, with a Computer Science minor, from the University of California, Berkeley. He continued his academic journey with a Master of Science and a Ph.D. in Electrical Engineering and earned an M.D. from Stanford University.

“ONI will immediately benefit from the expertise Alex brings to the table supported by an exceptional track record commercializing impactful technologies across life science and healthcare industries,” said Paul Scagnetti, ONI’s Chief Executive Officer. “Alex’s partnership will help us realize ONI’s mission faster and with greater impact to research and therapeutics everywhere.”

ONI is excited to have Dr. Alex Aravanis join our board of directors, as his remarkable background and accomplishments will undoubtedly contribute to our organization’s continued growth and success. We look forward to benefiting from his insights and leadership as we pursue new opportunities and advancements in our field.

For media inquiries, please contact:
Jason Jell
Vice President of Marketing
jason@oni.bio
1.716.393.1163